BioAge Labs (BIOA) Debt to Equity (2023 - 2026)

BioAge Labs has disclosed Debt to Equity across 4 years of filings, most recently posting $0.0 for Q1 2026.

• Debt to Equity for Q1 2026 came in at $0.0, down 86.43% year-over-year; the trailing twelve-month figure through Mar 2026 was $0.0 (down 86.43% YoY), and the FY2025 annual result was $0.01, down 63.01% from the prior year.
• Debt to Equity came in at $0.0 for Q1 2026 at BioAge Labs, down from $0.01 in the prior quarter.
• In the past five years, Debt to Equity ranged from a high of $0.03 in Q3 2024 to a low of -$0.08 in Q4 2023.
• The 4-year median for Debt to Equity is $0.02 (2025), against an average of $0.01.
• Across the five-year window, Debt to Equity jumped 132.13% in 2024 and sank 86.43% in 2026, its largest moves.
• BioAge Labs' Debt to Equity stood at -$0.08 in 2023, then jumped by 132.13% to $0.03 in 2024, then slumped by 63.01% to $0.01 in 2025, then sank by 68.59% to $0.0 in 2026.
• The last three Debt to Equity figures came in at $0.0 (Q1 2026), $0.01 (Q4 2025), and $0.01 (Q3 2025), per Business Quant data.